Phosphospecific flow cytometry for pharmacodynamic drug monitoring: Analysis of the JAK-STAT signaling pathway

Department of Internal Medicine, Erasmus MC, University medical Hospital Rotterdam, The Netherlands.
Clinica chimica acta; international journal of clinical chemistry (Impact Factor: 2.82). 01/2012; 413(17-18):1398-405. DOI: 10.1016/j.cca.2011.12.023
Source: PubMed


Cytokines of the IL-2 receptor family act via activation of the JAK-STAT (janus tyrosine kinase-signal transducer and activator of transcription) signaling pathway. These cytokines are pivotal for the development and function of lymphocyte subsets involved in the immune response after organ transplantation including T, B and natural killer cells. The new small drug molecule and JAK1/3 inhibitor, tofacitinib, is currently being tested in phase II and III clinical trials for rheumatoid arthritis, psoriasis and in organ transplantation. This agent specifically targets the JAK-STAT signaling pathway. Here we discuss phosphospecific flow cytometry as a novel tool to monitor the JAK-STAT signaling pathway in kidney transplant patients and speculate that through the use of this pharmacodynamic tool the efficacy of immunosuppressive drugs can be assessed enabling optimization of the immunosuppressive therapy for individual transplant patients.

Download full-text


Available from: Carla C Baan, Oct 20, 2014
1 Follower
40 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The common γ-chain (γc) cytokines signal through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway and play pivotal roles in lymphocyte activation. We investigated the effect of immunosuppressive drugs targeting this pathway, the JAK inhibitor tofacitinib (CP-690,550) and the anti-interleukin (IL)-2R antibody basiliximab, as part of a phase 2 study. After whole-blood activation with the γc cytokines IL-2, IL-7, and IL-15, STAT5 phosphorylation was determined in T cells of de novo kidney transplantation patients treated with tofacitinib/basiliximab (n=5), calcineurin inhibitor (CNI) (cyclosporine A)/basiliximab (n=4) or CNI (tacrolimus)-based immunosuppression (n=6). The IC50 for phosphorylated STAT (P-STAT) 5 inhibition by tofacitinib was determined in cytokine-activated CD4 and CD8 T cells from healthy individuals (n=4). IC50 was 26, 72, and 37 ng/mL for IL-2, IL-7, and IL-15 activation, in CD4 T cells, respectively; and 35, 61, and 76 ng/mL for IL-2, IL-7, and IL-15 activation, in CD8 T cells, respectively. In kidney transplantation patients, 7 days after starting tofacitinib/basiliximab treatment, cytokine-induced P-STAT5 was inhibited in CD4 T cells (92% for IL-2 activation, 60% for IL-7, and 75% for IL-15), which persisted for the 2-month study period. In contrast, CNI/basiliximab treatment did not affect IL-7-activated or IL-15-activated P-STAT5; only IL-2-activated P-STAT5 was reduced by 77% on day 7 and recovered to pretreatment levels within 2 months. CD8 T cells showed a comparable profile to CD4 T cells. P-STAT5 was not inhibited in CNI-treated control patients. Tofacitinib therapy strongly inhibits γc cytokine-induced JAK/STAT5 activation, whereas basiliximab suppresses IL-2-stimulated activation only. Pharmacodynamic monitoring offers a unique tool to evaluate the biologic effects of immunosuppressive drugs.
    Transplantation 09/2012; 94(5):465-72. DOI:10.1097/TP.0b013e3182626b5a · 3.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Psoriasis is a chronic inflammatory disease of the skin. The causes of psoriasis are unknown, although family and twin studies have shown genetic factors to play a key role in its development. The many genes associated with psoriasis and the immune response include TNF α , IL23, and IL12. Advances in knowledge of the pathogenesis of psoriasis have enabled the development of new drugs that target cytokines (e.g., etanercept, adalimumab, and infliximab, which target TNF α , and ustekinumab, which targets the p40 subunit of IL23 and IL12). These drugs have improved the safety and efficacy of treatment in comparison with previous therapies. However, not all patients respond equally to treatment, possibly owing to interindividual genetic variability. In this review, we describe the genes associated with psoriasis and the immune response, the biological drugs used to treat chronic severe plaque psoriasis, new drugs in phase II and III trials, and current knowledge on the implications of pharmacogenomics in predicting response to these treatments.
    08/2013; 2013(3):613086. DOI:10.1155/2013/613086
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: My research found that cell-free DNA (cfDNA) derived from the transplanted organ (GcfDNA, graft-derived cell-free DNA) is a clinically promising biomarker for the direct determination of organ damage in the sense of a "liquid biopsy". All that is required for this is a simple blood sample from the recipient. In contrast to conventional markers of organ function, organ integrity assessment is immediate, direct and highly specific. Recent developments in laboratory diagnostics such as digital droplet PCR (ddPCR) have made it possible to use this marker as a routine clinical test. The results are produced at relatively low cost and within one working day. Immediately after transplantation, very high concentrations of cfDNA derived from the donor organ (GcfDNA) were found in all patients. Within a few days, the values dropped rapidly and reached values found in stable liver transplant recipients, which are below 10%. However, no correlation was found between initial GcfDNA release and reperfusion / ischemia damage. In case of insufficient immunosuppression, increased GcfDNA values were observed. GcfDNA as a general marker of organ integrity is suitable to assess the joint effects of various immunosuppressive agents and values are inversely proportional to the combined effects of immunosuppressive therapy. Patients with acute rejection had GcfDNA values above 50%. GcfDNA was able to identify subclinical rejection episodes and allows for the timely initiation of interventions. An increase in the GcfDNA was evident several days before clinically manifested acute rejection. Also, virus-associated graft injury caused by hepatitis C resulted in comparatively higher GcfDNA values. In the presence of cholestasis however, no increase in GcfDNA values was seen. Immunosuppressive therapy could become safer, easier, more reliable, and individualized by the routine use of GcfDNA. Rejection episodes caused by subtherapeutic immunosuppression could be diagnosed earlier in the subclinical phase. This could shift the emphasize in immunosuppressive therapy away from mere reaction to clinical events towards prevention instead. To achieve the goal of personalized medicine, immunosuppression could be adapted to match each patient's individual optimum therapeutic needs rather than the current practice of prefixed dosing. Reduced side effects and a reduction in healthcare costs would be a consequence. This marker could also help to achieve the final goal of improving the long-term graft and recipient survival after solid organ transplantation. Multicenter studies for the validation of this marker prior to its routine use are already underway.
    09/2014, Degree: Dr. med. dent. (DMD), Supervisor: Michael Oellerich
Show more